Gastric Cancer, Organoids
Conditions
Brief summary
The study is a real-world observational clinical study. Patients diagnosed as gastric cancer through histopathology were screened and enrolled. Before anti-tumor treatment, gastroscopy biopsy tissue specimens, surgical specimens, and malignant pleural effusion or ascites specimens, etc. are collected. The investigators will perform a drug sensitivity testing based on a novel drug susceptibility testing method to test the commonly used anti-tumor treatment regimens. Patients were given conventional anti-tumor treatment according to the medical judgment of the doctors. Finally, the investigator will evaluate the consistency of clinical efficacy in gastric cancer treatment and drug susceptibility outcomes.
Interventions
None listed
Sponsors
Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences
Precedo Pharmaceuticals Co. Ltd.
Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China
Funan Liu
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
1. Male or female, aged ≥ 18 and ≤80; 2. Patients with gastric cancer diagnosed by histopathology; 3. Patients who need neoadjuvant treatment; adjuvant therapy after radical surgery or palliative treatment; 4. Fresh tumor tissue specimens or malignant pleural effusion or ascites can be obtained; 5. Patients who sign the informed consent form, and are able to comply with the study period treatment process.
Exclusion criteria
1. Inability to follow the research protocol; 2. Inability to obtain relevant fresh specimens by biopsy/surgery/puncture; 3. Concomitant contraindications to chemotherapy; 4. pregnant or lactating women; 5. Patients deemed inappropriate by investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | From date of surgery until the date of first documented recurrence，up to 3 years | An Indicator of efficacy of postoperative adjuvant therapy |
| Sensitivity | Through study completion, an average of 1 year | Cases in which drug susceptibility results are sensitive to the antineoplastic regimen as a percentage of the cases that are effective in clinical evaluation |
| Specificity | Through study completion, an average of 1 year | Cases in which drug susceptibility results are resistance to the antineoplastic regimen as a percentage of the cases that are ineffective in clinical evaluation |
Countries
China
Contacts
Primary ContactShuhui Song, bachelor
Outcome results
None listed